-
公开(公告)号:US5516764A
公开(公告)日:1996-05-14
申请号:US219236
申请日:1994-03-28
申请人: Ryoichi Osawa , Isao Suda , Masaaki Numata , Mamoru Sugimoto , Kenkichi Tomita , Nobuyuki Kibushi , Takayuki Ishii , Naokazu Sugiyama , Makiko Kasano , Tae Yasunaga , Makoto Tanaka , Tomoya Ogawa , Mariko Ishii
发明人: Ryoichi Osawa , Isao Suda , Masaaki Numata , Mamoru Sugimoto , Kenkichi Tomita , Nobuyuki Kibushi , Takayuki Ishii , Naokazu Sugiyama , Makiko Kasano , Tae Yasunaga , Makoto Tanaka , Tomoya Ogawa , Mariko Ishii
IPC分类号: C12P19/04 , A61K31/70 , A61K31/715 , A61P7/02 , A61P13/02 , A61P15/00 , A61P37/08 , C07H13/04 , C12R1/01 , A01N43/04 , C07H1/00
CPC分类号: A61K31/715 , A61K31/70 , A61K31/7012 , A61K31/7016 , A61K31/702 , C07H13/04 , Y10S514/825 , Y10S514/885
摘要: An anti-inflammatory drug comprising as the effective component at least one compound selected from the group consisting of colominic acid, partial hydrolysis products of colominic acid and pharmaceutically acceptable salts thereof. The drug is used as a drug for renal diseases, a drug for hepatitis, an immunomodulator and a drug for inhibiting the chemotaxis of neutrophil.
摘要翻译: 一种抗炎药,其包含选自科洛芬酸,聚洛米酸的部分水解产物和其药学上可接受的盐中的至少一种化合物作为有效成分。 该药用作肾脏疾病的药物,用于肝炎的药物,免疫调节剂和抑制嗜中性粒细胞趋化性的药物。
-
公开(公告)号:US5668115A
公开(公告)日:1997-09-16
申请号:US450699
申请日:1995-05-25
申请人: Ryoichi Osawa , Isao Suda , Masaaki Numata , Mamoru Sugimoto , Kenkichi Tomita , Nobuyuki Kibushi , Takayuki Ishii , Naokazu Sugiyama , Makiko Kasano , Tae Yasunaga , Makoto Tanaka , Tomoya Ogawa , Mariko Ishii
发明人: Ryoichi Osawa , Isao Suda , Masaaki Numata , Mamoru Sugimoto , Kenkichi Tomita , Nobuyuki Kibushi , Takayuki Ishii , Naokazu Sugiyama , Makiko Kasano , Tae Yasunaga , Makoto Tanaka , Tomoya Ogawa , Mariko Ishii
IPC分类号: C12P19/04 , A61K31/70 , A61K31/715 , A61P7/02 , A61P13/02 , A61P15/00 , A61P37/08 , C07H13/04 , C12R1/01
CPC分类号: A61K31/715 , A61K31/70 , A61K31/7012 , A61K31/7016 , A61K31/702 , C07H13/04 , Y10S514/825 , Y10S514/885
摘要: An anti-inflammatory drug comprising as the effective component at least one compound selected from the group consisting of colominic acid, partial hydrolysis products of colominic acid and pharmaceutically acceptable salts thereof. The drug is used as a drug for renal diseases, a drug for hepatitis, an immunomodulator and a drug for inhibiting the chemotaxis of neutrophil.
摘要翻译: 一种抗炎药,其包含选自科洛芬酸,聚洛米酸的部分水解产物和其药学上可接受的盐中的至少一种化合物作为有效成分。 该药用作肾脏疾病的药物,用于肝炎的药物,免疫调节剂和抑制嗜中性粒细胞趋化性的药物。
-
公开(公告)号:US5763420A
公开(公告)日:1998-06-09
申请号:US450930
申请日:1995-05-25
申请人: Ryoichi Osawa , Isao Suda , Masaaki Numata , Mamoru Sugimoto , Kenkichi Tomita , Nobuyuki Kibushi , Takayuki Ishii , Naokazu Sugiyama , Makiko Kasano , Tae Yasunaga , Makoto Tanaka , Tomoya Ogawa , Mariko Ishii
发明人: Ryoichi Osawa , Isao Suda , Masaaki Numata , Mamoru Sugimoto , Kenkichi Tomita , Nobuyuki Kibushi , Takayuki Ishii , Naokazu Sugiyama , Makiko Kasano , Tae Yasunaga , Makoto Tanaka , Tomoya Ogawa , Mariko Ishii
IPC分类号: C12P19/04 , A61K31/70 , A61K31/715 , A61P7/02 , A61P13/02 , A61P15/00 , A61P37/08 , C07H13/04 , C12R1/01 , A61K31/735
CPC分类号: A61K31/715 , A61K31/70 , A61K31/7012 , A61K31/7016 , A61K31/702 , C07H13/04 , Y10S514/825 , Y10S514/885
摘要: An anti-inflammatory drug comprising as the effective component at least one compound selected from the group consisting of colominic acid, partial hydrolysis products of colominic acid and pharmaceutically acceptable salts, thereof. The drug is used as a drug for renal diseases, a drug for hepatitis, an immunomodulator and a drug for inhibiting the chemotaxis of neutrophil.
摘要翻译: 一种抗炎药,其包含选自科洛芬酸,聚洛米酸的部分水解产物和其药学上可接受的盐的至少一种化合物作为有效成分。 该药用作肾脏疾病的药物,用于肝炎的药物,免疫调节剂和抑制嗜中性粒细胞趋化性的药物。
-
公开(公告)号:US5945404A
公开(公告)日:1999-08-31
申请号:US927399
申请日:1997-09-10
申请人: Kei Sugai , Motoaki Goto , Satoshi Yoshida , Yumiko Noda , Takayuki Ishii , Nobuyuki Kibushi , Hutoshi Nishikawa
发明人: Kei Sugai , Motoaki Goto , Satoshi Yoshida , Yumiko Noda , Takayuki Ishii , Nobuyuki Kibushi , Hutoshi Nishikawa
CPC分类号: C07J43/003 , C07J17/005 , C07J41/005
摘要: A glycoside represented by formula (I), wherein dexamethasone or betamethasone is the aglycon and the 21-position is substituted by a simple sugar or an acylated sugar selected from the group consisting of glucose, galactose, mannose, rhamnose, fucose, N-acetylglucosamine, N-acetylgalactosamine, galacturonic acid, glucuronic acid and sialic acid. ##STR1##
摘要翻译: 由式(I)表示的糖苷,其中地塞米松或倍他米松是糖苷配基,21位被选自葡萄糖,半乳糖,甘露糖,鼠李糖,岩藻糖,N-乙酰葡糖胺的单糖或酰化糖取代 ,N-乙酰半乳糖胺,半乳糖醛酸,葡糖醛酸和唾液酸。
-
-
-